Amanote Research
Register
Sign In
Larotrectinib Has Antitumor Activity in TRK + Pediatric Solid Tumors
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2018-063
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
April 13, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Larotrectinib OK'd for Cancers With TRK Fusions
Cancer Discovery
Oncology
Surgical Management in Pediatric Malignant Solid Tumors
Journal of Nihon University Medical Association
Abstract P6-20-02: Activity of Larotrectinib, a Highly Selective Inhibitor of Tropomyosin Receptor Kinase, in TRK Fusion Breast Cancers
A Developed STING Agonist Has Systemic Antitumor Activity
Cancer Discovery
Oncology
Local Delivery of IFNα Has Antitumor Activity in Bladder Cancer
Cancer Discovery
Oncology
Abstract PR07: A Pediatric Phase 1 Study of Larotrectinib, a Highly Selective Inhibitor of the Tropomyosin Receptor Kinase (TRK) Family: An Updated Analysis
GPRC5D CAR T-Cell Therapy Has Antitumor Activity in Multiple Myeloma
Cancer Discovery
Oncology
L-Blp25 Vaccine Plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice
Clinical Cancer Research
Cancer Research
Oncology
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
Clinical Cancer Research
Cancer Research
Oncology
